首页> 外文期刊>Respiratory Medicine Case Reports >Therapeutic effect of nintedanib on acute exacerbation of interstitial lung diseases
【24h】

Therapeutic effect of nintedanib on acute exacerbation of interstitial lung diseases

机译:Nintedanib对间质性肺疾病急性加重的治疗作用

获取原文
           

摘要

Although the development of new antifibrotic agents (pirfenidone, nintedanib) has modified the disease progression of idiopathic pulmonary fibrosis (IPF), there is still no effective treatment for acute exacerbation of interstitial lung diseases (ILD) including IPF. We herein report a case of acute exacerbation of ILD (AE-ILD) treated only with nintedanib without any environmental changes and any other medications such as corticosteroid therapy, diuretic and anti-biotics, which resulted in the gradual improvement of the patient's clinical symptoms, high-resolution computed tomography findings, and forced vital capacity. This case might suggest the possibility that nintedanib not only modifies the disease progression of Idiopathic Pulmonary Fibrosis (IPF), but also facilitate the recovery from the acute exacerbation of ILD.
机译:尽管新的抗纤维化药物(吡非尼酮,nintedanib)的开发已改善了特发性肺纤维化(IPF)的疾病进展,但仍没有有效的方法治疗包括IPF在内的间质性肺疾病(ILD)。我们在此报告了一例仅用nintedanib治疗而没有任何环境变化和任何其他药物(例如皮质类固醇疗法,利尿剂和抗生素)治疗的ILD(AE-ILD)急性加重病例,从而导致患者的临床症状逐步改善,高分辨率计算机断层扫描结果和强制肺活量。这种情况可能表明,任尼达尼不仅可能改变特发性肺纤维化(IPF)的疾病进程,而且还可能促进ILD急性加重的恢复。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号